PMID- 35335889
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220329
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 14
IP  - 3
DP  - 2022 Feb 25
TI  - Effect of Thrombopoietin Receptor Agonist on Pregnant Mice.
LID - 10.3390/pharmaceutics14030514 [doi]
LID - 514
AB  - Thrombopoietin receptor agonists (TPO-RAs) are an effective treatment for 
      refractory immune thrombocytopenia (ITP). However, the use of TPO-RAs is limited 
      for ITP in pregnant women due to concerns about fetal toxicity. In this study, we 
      examined the effects of romiplostim, one of the TPO-RAs, on pregnant mice. The 
      mice were injected subcutaneously with romiplostim (1, 5, 10, 30, and 100 mug/kg) 
      on gestational days (GD) 1, 8, and 15. We evaluated maternal and fetal platelet 
      and megakaryocyte counts (MK), fetal weight at birth, placental morphology, and 
      miscarriage rates. Romiplostim increased platelet and MK counts in pregnant mice 
      at all doses and in fetuses at doses above 10 microg/kg. Fetal weight at birth was 
      slightly reduced at a dose of 100 mug/kg, but there were no significant 
      differences in placental weight, spiral artery wall thickness, placental growth 
      factor signal changes, or the rate of resorption at that dosage. The dose of 
      romiplostim used clinically for ITP patients (1-10 mug/kg) did not show any 
      adverse effects on pregnant mice. Although the results of the present study are 
      encouraging, until there are more conclusive data, the use of romiplostim should 
      be evaluated individually in severe, life-threatening cases, and all relevant 
      ethical aspects should be considered.
FAU - Nakai, Kensaku
AU  - Nakai K
AD  - Department of Obstetrics and Gynecology, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi Abeno-ku Osaka, Osaka 545-8585, Japan.
FAU - Misugi, Takuya
AU  - Misugi T
AD  - Department of Obstetrics and Gynecology, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi Abeno-ku Osaka, Osaka 545-8585, Japan.
FAU - Kitada, Kohei
AU  - Kitada K
AD  - Department of Obstetrics and Gynecology, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi Abeno-ku Osaka, Osaka 545-8585, Japan.
FAU - Kurihara, Yasushi
AU  - Kurihara Y
AD  - Department of Obstetrics and Gynecology, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi Abeno-ku Osaka, Osaka 545-8585, Japan.
FAU - Tahara, Mie
AU  - Tahara M
AD  - Department of Obstetrics and Gynecology, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi Abeno-ku Osaka, Osaka 545-8585, Japan.
FAU - Hamuro, Akihiro
AU  - Hamuro A
AD  - Department of Obstetrics and Gynecology, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi Abeno-ku Osaka, Osaka 545-8585, Japan.
FAU - Nakano, Akemi
AU  - Nakano A
AUID- ORCID: 0000-0002-6666-5924
AD  - Department of Obstetrics and Gynecology, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi Abeno-ku Osaka, Osaka 545-8585, Japan.
FAU - Koyama, Masayasu
AU  - Koyama M
AD  - Department of Obstetrics and Gynecology, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi Abeno-ku Osaka, Osaka 545-8585, Japan.
FAU - Kira, Yukimi
AU  - Kira Y
AD  - Department of Research Support Platform, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi Abeno-ku Osaka, Osaka 545-8585, Japan.
FAU - Tachibana, Daisuke
AU  - Tachibana D
AUID- ORCID: 0000-0001-9268-2747
AD  - Department of Obstetrics and Gynecology, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi Abeno-ku Osaka, Osaka 545-8585, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220225
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC8951389
OTO - NOTNLM
OT  - immune thrombocytopenia (ITP)
OT  - pregnancy
OT  - romiplostim
OT  - thrombopoietin receptor agonists (TPO-RAs)
COIS- No conflict of interest.
EDAT- 2022/03/27 06:00
MHDA- 2022/03/27 06:01
PMCR- 2022/02/25
CRDT- 2022/03/26 01:04
PHST- 2022/01/27 00:00 [received]
PHST- 2022/02/21 00:00 [revised]
PHST- 2022/02/22 00:00 [accepted]
PHST- 2022/03/26 01:04 [entrez]
PHST- 2022/03/27 06:00 [pubmed]
PHST- 2022/03/27 06:01 [medline]
PHST- 2022/02/25 00:00 [pmc-release]
AID - pharmaceutics14030514 [pii]
AID - pharmaceutics-14-00514 [pii]
AID - 10.3390/pharmaceutics14030514 [doi]
PST - epublish
SO  - Pharmaceutics. 2022 Feb 25;14(3):514. doi: 10.3390/pharmaceutics14030514.